A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia

I-CGI-C Results confirmed improved outcomes at Week 12, with scores that were similar between the gradual- and immediate-switch groups, respectively, for risperidone, 2.82 and 2.67 (95% CI: − 0.229, 0.511); olanzapine, 2.87 and 3.03 (95% CI: − 0.548, 0.235); and aripiprazole, 2.79 and 2.81 (95% CI: − 0.405, 0.368). Incidence of adverse events (AEs) was similar in both switch groups, with the most frequently reported (≥ 10%) being dizziness, dry mouth, somnolence, and weight increase. In conclusion, switching to iloperidone by either a gradual or an immediate method did not reveal any clinically significant differences in ratings of overall efficacy and safety/tolerability outcomes, based on the I-CGI-C at 12 weeks. Similar overall safety/AE profiles were observed regardless of the specific agent from which patients were switched.